Gilead Covid-19 Drug May Exceed $2 Billion Sales, Piper Says
Signage is displayed outside Gilead Sciences headquarters in California. (Photographer: David Paul Morris/Bloomberg)

Gilead Covid-19 Drug May Exceed $2 Billion Sales, Piper Says

(Bloomberg) -- At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.’s new medicine could be reasonably priced and still generate over $2 billion in revenue for the biot...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.